Search or ask a question

What are the types of sickelcell Anemia?

Sickle cell anemia

Hemoglobinopathy

Hemoglobin SC Disease

Abnormal hemoglobin

Best insight from top research papers

Sickle cell anemia is a hemoglobinopathy characterized by the inheritance of two abnormal hemoglobin genes, at least one of which is the sickle hemoglobin gene. The most common types of sickle cell disease are hemoglobin SS disease, hemoglobin SC disease, and hemoglobin S-thalassemia .

Answers from top 3 papers

PDF

Open Access

More filters

Papers (3)	Insight
Open access•Journal Article•DOI Anemia de Células Falciformes: Correlación Clínico-Patológica María Antonia Correa Saavedra 11 Mar 2019 2 Citations	The paper does not mention the specific types of sickle cell anemia.
Journal Article•DOI Hemolytic Anemia: Part 2 Kwesi Sackey 01 Jun 1999-Pediatrics in Review 8 Citations	The paper mentions three types of sickle cell disease: hemoglobin SS disease, hemoglobin SC disease, and hemoglobin S-thalassemia.
Book Chapter•DOI Sickle Cell Anemia D.J. Weatherall 01 Jan 2013 1 Citations	The paper does not mention the types of sickle cell anemia.

My columns

Related Questions

What are the prevelance of sickelcell Anemia in Chattisgarh?5 answersThe prevalence of sickle cell anemia in Chhattisgarh is reported to be 10.6% among the population of three districts (Kanker, Dantewada, and Raigarh). Additionally, the prevalence of sickle cell trait (HbAS) was found to be 10% among different tribes in Chhattisgarh. Another study conducted in Sirohi district of Rajasthan state reported a prevalence of 9.2% for sickle cell anemia among the Garasia tribe.

What are the different types of leukemia?5 answersLeukemia is a type of blood cancer that can be categorized into four types: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). AML and ALL are acute forms of leukemia that progress quickly, while CLL and CML are chronic forms that progress slowly. Each type of leukemia affects different types of cells in the blood and bone marrow, leading to abnormal cell growth and function. The identification of specific biological processes and pathways related to each type of leukemia is important for determining the underlying pathogenesis and developing targeted therapies. Understanding the different types of leukemia is crucial for accurate diagnosis, treatment, and management of the disease.

What are the types of clonal hematopoiesis?5 answersClonal hematopoiesis (CH) can occur through somatic genetic alterations or genetic drift. Somatic genetic alterations observed in CH include point mutations in cancer-related genes and mosaic chromosomal alterations. In the context of bone marrow failure states or exposure to chemotherapy and radiation therapy, CH can arise due to context-specific selection pressures and constraint-escape mechanisms. In aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH), CH can be affected by karyotypic abnormalities and genetic mutations, which should be distinguished from MDS clone. CH is also detected in patients undergoing cellular therapies such as autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy, with different implications for each treatment method. Somatic mosaicism, including clonal hematopoiesis, is prevalent in elderly individuals and is associated with an increased risk of age-related diseases, particularly cardiovascular disease. Sex-specific differences in the mutational patterns of clonal hematopoiesis have been observed, with certain mutations enriched in males and others in females.

What is the prevalence of sickle cell anemia?5 answersThe prevalence of sickle cell anemia varies across different populations. In the Lagoa de Maria Clemência and Oiteiro communities in Bahia, Brazil, the prevalence of sickle cell anemia was found to be 4.1% among individuals aged 10 years or older. Sickle cell anemia is also prevalent in Africa, the Middle East, and parts of India, particularly in areas where malaria is widespread. In the United States, sickle cell anemia affects approximately 1 in 500 African Americans, with about 300,000 infants born with the disease annually. Globally, it is estimated that there are about 300,000 individuals born with sickle cell anemia, and this number is expected to rise to 400,000 by 2050. The disease is prevalent in many areas of the world, including Africa, the Middle East, and parts of India.

What are the types of abnormal haemoglobin?5 answersAbnormal haemoglobins can be classified into different types based on their structural abnormalities and clinical significance. These include sickle cell disorders and thalassaemias. Abnormal haemoglobins can be detected by various methods, and the presence of small amounts of foetal haemoglobin can be identified through a combination of these methods. Most abnormal hemoglobins are rare, with over 300 types reported by 1983, but only a few are clinically significant. These disorders often involve single base substitutions, additions, deletions, or fusions of amino acids in the α or β globin chains. Hemoglobinopathies rarely affect the δ or γ chains, which are present in hemoglobin A2 or fetal hemoglobin. Additionally, the synthesis of α or β chains may be diminished in thalassemia syndromes.

What are the different types of S?2 answersThere are three different types of S mentioned in the abstracts. Type 1 (utricle) is characterized by upward deviation of both eyes with different amplitudes. Type 2 (dorsolateral medulla oblongata) involves hypertropia of one eye while the other eye remains in the primary position. Type 3 (midbrain tegmentum) is characterized by simultaneous hypertropia of one eye and hypotropia of the other eye.

See what other people are reading

What is the mechanism of increasing fetal hemoglobin in hydroxyurea users?

How ocupational hemopathies are prevented?

How hb o arab migrates in alkaline electrophoresis?

Does blood group of AS exacerbate G6PD deficiency outcomes?

What is thalassemia?

Thalassemia is a group of inherited blood disorders characterized by abnormal hemoglobin production, leading to anemia. It results from mutations in the genes responsible for producing alpha- or beta-globin chains of hemoglobin, causing ineffective erythropoiesis and premature red blood cell destruction. Thalassemia can manifest in various forms, such as alpha-thalassemia major causing hydrops fetalis and beta-thalassemia major requiring lifelong transfusions. Treatment options include blood transfusions, iron chelation therapy, stem cell transplantation, and gene therapy. Complications like iron overload, cardiac issues, and endocrine disorders can arise, impacting the quality of life and necessitating comprehensive management. Thalassemia poses significant challenges to patients and their families, emphasizing the importance of early detection and appropriate interventions to improve outcomes.CRISPR for gene therapy?

CRISPR technology has revolutionized gene therapy by offering precise gene editing capabilities. While ethical concerns exist regarding CRISPR gene therapy, there are no intrinsic objections to its use, emphasizing the importance of a practical moral framework for decision-making and public engagement. In the realm of treating genetic disorders like cystinosis, CRISPR has shown promise through the creation of novel mouse models and the use of viral vectors for treatment. Moreover, non-viral CRISPR delivery systems have emerged as a safer and more efficient option for cancer gene editing, addressing limitations associated with viral vectors. Efforts to enhance CRISPR safety include the development of time-delayed safety switches to mitigate off-target effects and immune responses, aiming to optimize gene therapy outcomes.What is the prevalence of genotype distribution in thalassemia in Europe?

The prevalence of genotype distribution in thalassemia in Europe varies, with significant hemoglobin trait prevalence ranging from about 1% across Europe to as high as 18% in Africa, while the prevalence of the disease itself is lower in Europe at 0.2/1000. Specific mutations such as IVSII-1 (G>A), CD36-37 (-T), IVSI-110 (G>A), --Med, and α3.7 are common in beta and alpha genes, with IVSII-1 (G>A) β0/β, CD36-37 (-T) β0/β, and IVSI-110 (G>A) β0/β being the most prevalent genotypes in thalassemia carriers in couples suspected of the disease. The data suggests that thalassemia prevalence in Europe is relatively lower compared to regions like Africa and Asia, where the prevalence is notably higher.COmplications of thalasemia?

Thalassemia presents a spectrum of complications affecting various organ systems. These include cardiovascular issues like cardiomyopathy, pulmonary hypertension, arrhythmias, and vasculopathies, which can lead to sudden cardiac death. Additionally, thalassemia can result in anemia, bone changes, impaired growth, and iron overload, impacting maternal and fetal outcomes during pregnancy. Patients with transfusion-dependent β-thalassemia are at high risk of cardiovascular diseases, endocrine disorders, and skeletal deformities, with cardiac pathology including myocardial dysfunction and arrhythmias. Furthermore, thalassemia complications can be exacerbated during the COVID-19 pandemic due to limited blood supply, malnutrition, psychological issues, and inadequate diagnostic and treatment procedures. Hypocalcemia is another complication seen in thalassemic patients, attributed to various factors like iron overload, drug effects, and genetic disorders.User what is thalasemia?

Thalassemia is a genetic blood disorder characterized by the body's inability to produce sufficient hemoglobin, leading to severe anemia. It is prevalent globally, with a carrier frequency of 3-4% in the Indian population. Thalassemia can manifest in different forms such as homozygous, heterozygous, and compound heterozygous, each with varying severity depending on the type of mutation present. Treatment options include blood transfusions and stem cell transplants, with complications like iron overload being common during treatment. Thalassemia can have significant impacts on individuals, affecting their interactions due to physical differences and necessitating special care and coping mechanisms from families. Early detection of mutations through methods like ARMS-PCR and Sanger sequencing is crucial for prenatal testing and prevention of affected births within families.What is thalasemia?

Thalassemia is a genetic blood disorder characterized by abnormal hemoglobin production, leading to the destruction of red blood cells and causing anemia. It is inherited through mutations in hemoglobin-producing genes. Thalassemia can be categorized into different types based on the severity of the mutation, with homozygous and compound heterozygous individuals being affected. Treatment typically involves blood transfusions to manage anemia, but complications like iron overload can arise. Pre-marital screening and prenatal diagnosis are crucial in preventing the spread of thalassemia. Despite being a major public health concern, thalassemia is often overlooked in global health assessments, impacting under-5 mortality rates. Novel therapies like bone marrow transplantation and gene therapy offer promising treatment options, although their availability varies across different countries.Etiology of thalasemia?

Thalassemia is primarily caused by mutations in the globin genes, leading to reduced or absent production of specific globin chains, resulting in ineffective erythropoiesis and hemolytic anemia. These mutations can be nucleotide substitutions, frameshift insertions/deletions, or point mutations on chromosomes 11 and 16. Thalassemia is classified into alpha and beta types, with alpha thalassemia affecting alpha globin proteins and beta thalassemia affecting beta globin proteins. The imbalance in globin chains disrupts hemoglobin function, leading to symptoms ranging from mild anemia to severe complications like growth retardation and skeletal abnormalities. Treatment involves blood transfusions, iron chelation therapy, and in severe cases, allogeneic stem cell transplant as a potential cure. Early molecular analysis is crucial for accurate diagnosis and management of thalassemia patients.